Remarkably, ibrutinib, a BTK inhibitor with potent pan-ErbB activity (134), has demonstrated protection from progression to severe COVID-19, albeit in a small number of patients (135), highlighting that clinical evaluation of these ErbB inhibitors is warranted. The gene discussed is EGFR; the disease is COVID-19.